A new study shows that younger people may have older biological ages suggesting that studying young people may help in finding cures for old age-related medical conditions.
A Juno and Celgene collaboration will focus on T cell therapeutics for cancer, one in eight people is pre-diabetic but a new study shows a willingness to change behavior if made aware of their risk.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medtronic highlighted a shift in its diabetes strategy towards smaller deals in the latest quarterly earnings report.
The vast majority of life sciences venture capital went to biotechnology, a PricewaterhouseCoopers report finds.
LuminaCare Solutions, a biotech software developer that produced a predictive analytics tool for calculating patient’s resistance profile to hospital acquired infections, is raising a fresh round of capital to do pilot studies in the U.S., South Africa and U.K. It comes against a backdrop of President Barack Obama’s initiative to make fighting the superbug threat […]
Looks like NEA will invest about $1 billion in healthcare startups over the next few years. Areas like immuno-oncology, electrophysiology and
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Pfizer is launching a new, competitive grant program that solicits research projects on the gene PCSK9’s role in cardiovascular disease. It marks yet another step in big pharma’s goal to directly plumb academia for insights on their own drug targets. The grant program, through Pfizer’s Aspire initiative (Advancing Science through Pfizer Investigator Research Exchange), will fund grants up […]
M&A may seem hot in the life sciences, but that and IPO activity is starting to cool across all sectors, according to a new report from the National Venture Capital Association. The first quarter of 2015 saw less than 20 venture-backed IPOs since the first quarter of 2013. Independent of sector, when it comes to deal size, this quarter […]
The idea of using debt to support businesses in healthcare and life sciences tends to be viewed warily and with good reason. At MidAmerica Healthcare Venture Forum this week, GE Capital senior vice president in life sciences Joe Hammer offered up some helpful insights on the different kinds of debt available to biotech and medical […]
When science fiction creeps toward a disturbing potential reality, it makes for very good TV. Season 3 of the BBC’s Orphan Black returns April 18, satiating fans of the action-packed, conspiracy drama that’s delivered with a beautiful biotech backdrop. A fringe research foundation has peppered the earth with a series of human clones. Some of […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Lux Capital is raising a $350 million fund, Lux Ventures 4, as Fierce Biotech has already noted. From my standpoint, without confirmation from the firm, it’s entirely possible that war chest will be used to invest in digital health and biotech companies. It also invests in energy and technology companies. But here’s a look at […]
Sometimes it’s difficult to tell if a story is going to be wildly popular or just barely make a splash. We’ve gone back to reflect on which ones really made an impression on readers. Here were the top 5 in the biotech and pharma category in 2014 (click the headlines to check out the whole […]
Some healthcare accelerators have been gradually warming up to accepting applicants that do not fill the criteria of a relatively short path to commercialization. Although there are plenty of health IT and mobile health companies, in an increasing number accelerators they sit alongside medical device, diagnostic and even biotechnology businesses. Health Wildcatters, a Dallas-based accelerator, […]
A company that developed a medical device sensor to review and process clinical lab tests with a minimal amount of blood has taken the top prize in Nokia's X Challenge for sensing technology.
Tech venture behemoth Arch Venture Partners has announced its eighth venture fund just closed with more than $400 million in subscriptions and, as co-founder and managing director Robert Nelson just told Forbes, it’s looking to fund companies with “contrarian philosophies.” Alex Konrad over at Forbes writes: That money will go to funding companies that cofounder and […]